Navigation Links
Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
Date:3/25/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, Trubion's next generation CD20 drug candidate, for the treatment of systemic lupus erythematosus (SLE). Based on Trubion's Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being evaluated in a Phase 1 clinical trial for rheumatoid arthritis (RA).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

SBI-087 is a humanized SMIP drug candidate that is directed against the CD20 antigen. The Phase 1 SBI-087 dose escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous or intravenous dose of SBI-087 in patients with SLE. The study will enroll patients who were diagnosed with SLE, based on the American College of Rheumatology Revised Criteria, more than six months prior to study initiation.

Preclinical data demonstrated that a single dose of SBI-087 resulted in more potent B-cell depletion in peripheral blood and lymphoid tissues than rituximab. The objective of the preclinical study conducted by Wyeth was to evaluate the pharmacokinetics and pharmacodynamics of SBI-087 following a single intravenous dose. Administration of SBI-087 resulted in dose-dependent B-lymphocyte depletion in peripheral blood and lymphoid tissues that was more profound and sustained in SBI-087-treated groups compared with rituximab.

"Initiation of the SBI-087 Phase 1 SLE clinical trial marks anothe
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
2. Trubion Announces Presentations at Upcoming Investor Conferences
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
6. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
7. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
8. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
9. Trubion Announces Presentations at April/May Investor Conferences
10. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
11. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... WASHINGTON , Jan. 14, 2014  3D Communications, a leading provider ... scientific, regulatory, business, and media events in the United ... its former associate Virginia Cox , JD, is returning to ... Virginia Cox re-joins 3D after more than two years ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... CITY, Calif., Jan. 7 Abaxis, Inc. (Nasdaq: ... manufacturing point-of-care blood analysis instruments for both the ... has entered into a license agreement for co-exclusive ... diagnostics in the professional marketplace for certain technologies ...
... Jan. 7 News briefs concerning economic,and business growth in ... Draper Labs Acquires Manufacturing Site in ... Draper Laboratory bought a 41,000-square-foot building,in St. Petersburg recently where ... the building, 10050 16th St. N., should be completed,in March ...
... 6 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... medical device,research and development outsourcing company with operations ... Dr. Ge Li, the Company,s Chairman and,Chief Executive ... Morgan,Healthcare Conference on Tuesday, January 13, 2009, at ...
Cached Biology Technology:ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 2Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 4WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference 2
(Date:4/18/2014)... population predicted to reach 9 billion by 2050 ... considers human-altered landscapes such as farmland, according to ... that supports it might be an increasingly scarce ... of the land surface is directly affected by ... impacts such as climate change. But what if ...
(Date:4/18/2014)... comet impacts can cause widespread ecological havoc, killing off ... But new research from Brown University shows that impacts ... the time of an impact. , A research team ... of leaves and preserved organic compounds lodged inside glass ... material could provide a snapshot of environmental conditions at ...
(Date:4/17/2014)... peptide inhibits RSV infection , Respiratory syncytial ... respiratory tract infections, generating life-threating illness in very ... therapies are limited. RSV enters host cells through ... six-helix fusogenic bundle. Small interfering peptides that prevent ... these peptides are highly susceptible to degradation. In ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... 2011 Robotics researchers at Ben-Gurion University of the Negev ... develop intelligent sensing and manipulation algorithms for robots that ... project is part of the European Union Seventh Framework ... will develop the scientific know-how and several prototype systems ...
... more than 4 billion nucleotides, a draft sequence of the ... American Association for the Advancement of Science (AAAS). , The ... Prize annually recognizes the author or authors of an outstanding ... the journal Science between June and the following ...
... disorder that can lead to life-threatening bleeding episodes is ... findings from a new international research project led by ... it determines the treatment decision," says Maha Othman, a ... who led the three-year research project on the rare ...
Cached Biology News:Ben-Gurion U. part of EU consortium to develop robots that selectively pick fruit 2Draft sequence of Neandertal genome wins the 2010 AAAS Newcomb Cleveland Prize, supported by Affymetrix 2
See product name for description....
NATIVE, ENZYME PORCINE TRYPSIN...
Polyethylene Glycol 8000, 1 kg. PEG 8000.Used in differential DNA precipitation. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Biology Products: